It appears that Catalyst Health Ventures, an investor in early stage healthcare companies, is looking to raise a new fund.
The firm disclosed a $33 million securities offering — with the first sale yet to occur — in a recently filed U.S. Securities and Exchange Commission document.
Managing partner Joshua Phillips declined to comment on plans for the fund, but according to Catalyst’s website, it focuses its investments in technologically advanced medical devices, diagnostics, instruments and drug development. Typically, the firm invests early and takes the lead on investments.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Portfolio companies include GI Dynamics Inc., Hansen Medical Inc. (NASDAQ:HNSN), Novazyme Pharmaceuticals (acquired by Genzyme in 2001) and 3-D scanning firm Lantos Technologies. Catalyst has also contributed to medical technology incubators Pavilion Medical Innovations and Seedling Enterprises.
Located in Boston, Catalyst concentrates its investments in the northeastern U.S.